Tyramine pharmacokinetics and reduced bioavailability with food

Journal of Clinical Pharmacology

Volumn 43, Issue 6, 2003, Pages 604-609

  VanDenBerg, Chad M ^a,c   Blob, Lawrence F ^b   Kemper, Eva M ^a   Azzaro, Albert J ^a  

^a Somerset Pharmaceuticals   (United States)

^b Potomac Clinical Trials   (United States)

^c NONE   (United States)

Author keywords

Bioavailability; Pharmacokinetics; Tyramine

Indexed keywords

TYRAMINE;

ADULT; ARTICLE; CLINICAL TRIAL; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; ENCAPSULATION; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MEAL; NORMAL HUMAN; PRESSOR RESPONSE;

EID: 0037906097     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003253425     Document Type: Article

References (16)

1. Da Prada M, Zurcher G, Wuthrich I, Haefely WE: On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm 1988;26(Suppl.):31-56.
2. Hasan F, McCrodden JM, Kennedy NP, Tipton KF: The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J Neural Transm 1988;26(Suppl.):1-9.
3. Schultz R, Antonin K-H, Hoffman E, Jedrychowski M, Nilsson E, Schick C, et al: Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 1989;46:528-536.
4. Squires RF: Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol 1972;5:355-370.
5. Blackwell B, Marley E, Price J, Taylor D: Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Brit J Psychiatry 1967;113:349-365.
6. Murphy DL, Sunderland T, Cohen RM: Monoamine oxidase inhibiting antidepressants: a clinical update. Psychiatr Clin North Am 1984;7:549-62.
7. Robinson DS, Nies A, Ravaris L, Ives JO, Bartlett D: Clinical pharmacology of phenelzine. Arch Gen Psychiatry 1978;35:629-635.
8. Berlin I, Zimmer R, Cournot A, Payan C, Pedarriosse AM, Puech AJ: Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther 1989;46:344-351.
9. Bieck PR, Antonin K-H: Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 1988;8:237-245.
10. Bieck PR, Antonin K-H: Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm 1989;28(Suppl.):21-31.
11. Bieck PR, Firkusny L, Schick C, Antonin K-H, Nilsson E, Schulz R, Schwenk M, et al: Monoamine oxides inhibition by phenelzine and brofaromine in healthy volunteers. Clin Pharmacol Ther 1989;45:260-269.
12. Simpson GM, Gratz SS: Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers. Clin Pharmacol Ther 1992;52:286-291.
13. Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL: Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 1985;86:432-437.
14. Korn A, Da Prada M, Raffesberg W, Allen S, Gasic S: Tyramine pressor effect in man: Studies with moclobemide, a novel reversible monoamine oxidase inhibitor. J Neural Transm 1988;26(Suppl.):57-71.
15. Korn A, Da Prada M, Raffesberg W, Gasic S, Eichler HG: Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol 1988;11:17-23.
16. 2/20mg selegiline transdermal system (STS) in healthy male volunteers. Abstract presented at the NCDEU 40th annual meeting, Boca Raton, FL, 2000.